Learn what 2021 might hold for deals
Read our 2021 midyear report
PwC’s 2020 M&A Integration Survey
The needs of pharmaceutical and life sciences consumers, physicians, health systems, payers and governments are changing rapidly. To address the implications and succeed in this increasingly complex, competitive environment, you’ll want to elevate your capabilities and deliver the value customers require. These modifications include rethinking and retooling business models, operations, strategies and execution so you can provide enhanced care delivery, diagnostics and therapeutics, payment systems, and wellness and support.
Companies must rethink and retool their business models, operations, strategies and execution so they can provide enhanced care delivery, diagnostics and therapeutics, payment systems, and wellness and support to meet the challenges of this shifting marketplace.
Now more than ever, navigating deals in the pharmaceutical and life sciences industry requires confident decision making to stay a step ahead of competitive forces and the ever-changing market dynamics. For those organizations that manage through the complexity inherent in deal making, the opportunities for value creation are compelling.
We understand that deals are dynamic. We’ve worked across deals of many shapes and sizes and can deliver on the plan that we’ll define together. We help you to drive the growth that develops a more profitable future: not just for this deal, but across your business for years to come.
Whether an acquisition or divestiture, IPO or debt offering, restructuring or alliance, our 20,000+ deals professionals have seen it before. But your business is unique to you. We embrace change and translate deal uncertainty to help you deliver optimal value.
US Pharmaceutical and Life Sciences Advisory Leader, PwC US
US Pharmaceutical & Life Sciences Deals Leader, PwC US